CTSE Antibody

Catalog No: #35666

Package Size: #35666-1 50ul #35666-2 100ul

Orders: order@signalwayantibody.com
Support: tech@signalwayantibody.com

Description

Product Name	CTSE Antibody
Host Species	Rabbit
Clonality	Polyclonal
Purification	Antigen affinity purification.
Applications	WB IHC
Species Reactivity	Human;Mouse
Specificity	The antibody detects endogenous levels of total CTSE protein.
Immunogen Type	Recombinant Protein
Immunogen Description	Fusion protein corresponding to a region derived from internal residues of human Cathepsin E
Conjugates	Unconjugated
Target Name	CTSE
Other Names	CATE
Accession No.	Swiss-Prot#: P14091NCBI Gene ID: 1510Gene Accssion: BC042537
SDS-PAGE MW	43kd
Concentration	0.28mg/ml
Formulation	Rabbit IgG in pH7.3 PBS, 0.05% NaN3, 50% Glycerol.
Storage	Store at -20°C

Application Details

Western blotting: 1:100-1:500

Immunohistochemistry: 1:25-1:100

Images



Gel: 8%SDS-PAGE
Lysates (from left to right): Human stomach cancer tissue
Amount of lysate: 40ug per lane
Primary antibody: 1/140 dilution
Secondary antibody dilution: 1/8000
Exposure time: 30 seconds



Immunohistochemical analysis of paraffin-embedded Human pancreatic cancer tissue using #35666 at dilution 1/10.

Background

The protein encoded by this gene is a gastric aspartyl protease that functions as a disulfide-linked homodimer. This protease, which is a member of the peptidase C1 family, has a specificity similar to that of pepsin A and cathepsin D. It is an intracellular proteinase that does not appear to be involved in the digestion of dietary protein and is found in highest concentration in the surface of epithelial mucus-producing cells of the stomach. It is the first aspartic proteinase expressed in the fetal stomach and is found in more than half of gastric cancers. It appears, therefore, to be an oncofetal antigen. Transcript variants utilizing alternative polyadenylation signals and two transcript variants encoding different isoforms exist for this gene.

Published Papers

el at., Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals potential therapeutic strategies. In Nat Commun on 2022 Nov 8 by Yan Li, Chen Xu, et al..PMID: 36347856, , (2022)

PMID:36347856

Note: This product is for in vitro research use only and is not intended for use in humans or animals.